Discovery of Reversible Inhibitors of KDM1A Efficacious in Acute Myeloid Leukemia Models
Lysine-specific demethylase 1 (LSD1 or KDM1A) is a FAD-dependent enzyme that acts as a transcription corepressor or coactivator by regulating the methylation status of histone H3 lysines K4 and K9, respectively. KDM1A represents an attractive target for cancer therapy. While, in the past, the main m...
Gespeichert in:
Veröffentlicht in: | ACS medicinal chemistry letters 2020-05, Vol.11 (5), p.754-759 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 759 |
---|---|
container_issue | 5 |
container_start_page | 754 |
container_title | ACS medicinal chemistry letters |
container_volume | 11 |
creator | Romussi, Alessia Cappa, Anna Vianello, Paola Brambillasca, Silvia Cera, Maria Rosaria Dal Zuffo, Roberto Fagà, Giovanni Fattori, Raimondo Moretti, Loris Trifirò, Paolo Villa, Manuela Vultaggio, Stefania Cecatiello, Valentina Pasqualato, Sebastiano Dondio, Giulio So, Chi Wai Eric Minucci, Saverio Sartori, Luca Varasi, Mario Mercurio, Ciro |
description | Lysine-specific demethylase 1 (LSD1 or KDM1A) is a FAD-dependent enzyme that acts as a transcription corepressor or coactivator by regulating the methylation status of histone H3 lysines K4 and K9, respectively. KDM1A represents an attractive target for cancer therapy. While, in the past, the main medicinal chemistry strategy toward KDM1A inhibition was based on the optimization of ligands that irreversibly bind the FAD cofactor within the enzyme catalytic site, we and others have also identified reversible inhibitors. Herein we reported the discovery of 5-imidazolylthieno[3,2-b]pyrroles, a new series of KDM1A inhibitors endowed with picomolar inhibitory potency, active in cells and efficacious after oral administration in murine leukemia models. |
doi_str_mv | 10.1021/acsmedchemlett.9b00604 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7236255</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2405336251</sourcerecordid><originalsourceid>FETCH-LOGICAL-a523t-4c50d78202093c5dc16a1e08454bec58442c211586736b8d3865390cbe2466923</originalsourceid><addsrcrecordid>eNqFkU9rGzEQxUVpaFI3XyHo2IsT_V_tpWAcpwmxCZQWchNa7WytdHflSrsGf_vK2A3xKacZmN-8kd5D6IqSa0oYvbEudVC7NXQtDMN1WRGiiPiALmgp9FTqQn5805-jzym9ZKQsCvIJnXMmuOSaXqDnW59c2ELc4dDgH5C75KsW8EO_9pUfQkz7wePtis7womm8s86HMWHf45kbB8CrHbTB13gJ4x_ovMWrUEObvqCzxrYJLo91gn7dLX7O76fLp-8P89lyaiXjw1Q4SepCM8JIyZ2sHVWWAtFCigqc1EIwxyiVWhVcVbrmWkleElcBE0qVjE_Qt4PuZqz2jkA_RNuaTfSdjTsTrDenk96vze-wNQXjikmZBb4eBWL4O0IaTJctgba1PeSPGiaI5HuUZlQdUBdDShGa1zOUmH0s5jQWc4wlL169feTr2v8cMsAOQBYwL2GMffbsPdV_ao-eag</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2405336251</pqid></control><display><type>article</type><title>Discovery of Reversible Inhibitors of KDM1A Efficacious in Acute Myeloid Leukemia Models</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>American Chemical Society Journals</source><creator>Romussi, Alessia ; Cappa, Anna ; Vianello, Paola ; Brambillasca, Silvia ; Cera, Maria Rosaria ; Dal Zuffo, Roberto ; Fagà, Giovanni ; Fattori, Raimondo ; Moretti, Loris ; Trifirò, Paolo ; Villa, Manuela ; Vultaggio, Stefania ; Cecatiello, Valentina ; Pasqualato, Sebastiano ; Dondio, Giulio ; So, Chi Wai Eric ; Minucci, Saverio ; Sartori, Luca ; Varasi, Mario ; Mercurio, Ciro</creator><creatorcontrib>Romussi, Alessia ; Cappa, Anna ; Vianello, Paola ; Brambillasca, Silvia ; Cera, Maria Rosaria ; Dal Zuffo, Roberto ; Fagà, Giovanni ; Fattori, Raimondo ; Moretti, Loris ; Trifirò, Paolo ; Villa, Manuela ; Vultaggio, Stefania ; Cecatiello, Valentina ; Pasqualato, Sebastiano ; Dondio, Giulio ; So, Chi Wai Eric ; Minucci, Saverio ; Sartori, Luca ; Varasi, Mario ; Mercurio, Ciro</creatorcontrib><description>Lysine-specific demethylase 1 (LSD1 or KDM1A) is a FAD-dependent enzyme that acts as a transcription corepressor or coactivator by regulating the methylation status of histone H3 lysines K4 and K9, respectively. KDM1A represents an attractive target for cancer therapy. While, in the past, the main medicinal chemistry strategy toward KDM1A inhibition was based on the optimization of ligands that irreversibly bind the FAD cofactor within the enzyme catalytic site, we and others have also identified reversible inhibitors. Herein we reported the discovery of 5-imidazolylthieno[3,2-b]pyrroles, a new series of KDM1A inhibitors endowed with picomolar inhibitory potency, active in cells and efficacious after oral administration in murine leukemia models.</description><identifier>ISSN: 1948-5875</identifier><identifier>EISSN: 1948-5875</identifier><identifier>DOI: 10.1021/acsmedchemlett.9b00604</identifier><identifier>PMID: 32435381</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Letter</subject><ispartof>ACS medicinal chemistry letters, 2020-05, Vol.11 (5), p.754-759</ispartof><rights>Copyright © 2020 American Chemical Society.</rights><rights>Copyright © 2020 American Chemical Society 2020 American Chemical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a523t-4c50d78202093c5dc16a1e08454bec58442c211586736b8d3865390cbe2466923</citedby><cites>FETCH-LOGICAL-a523t-4c50d78202093c5dc16a1e08454bec58442c211586736b8d3865390cbe2466923</cites><orcidid>0000-0003-4915-5903 ; 0000-0003-0367-8290</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.9b00604$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acsmedchemlett.9b00604$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,2765,27076,27924,27925,53791,53793,56738,56788</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32435381$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Romussi, Alessia</creatorcontrib><creatorcontrib>Cappa, Anna</creatorcontrib><creatorcontrib>Vianello, Paola</creatorcontrib><creatorcontrib>Brambillasca, Silvia</creatorcontrib><creatorcontrib>Cera, Maria Rosaria</creatorcontrib><creatorcontrib>Dal Zuffo, Roberto</creatorcontrib><creatorcontrib>Fagà, Giovanni</creatorcontrib><creatorcontrib>Fattori, Raimondo</creatorcontrib><creatorcontrib>Moretti, Loris</creatorcontrib><creatorcontrib>Trifirò, Paolo</creatorcontrib><creatorcontrib>Villa, Manuela</creatorcontrib><creatorcontrib>Vultaggio, Stefania</creatorcontrib><creatorcontrib>Cecatiello, Valentina</creatorcontrib><creatorcontrib>Pasqualato, Sebastiano</creatorcontrib><creatorcontrib>Dondio, Giulio</creatorcontrib><creatorcontrib>So, Chi Wai Eric</creatorcontrib><creatorcontrib>Minucci, Saverio</creatorcontrib><creatorcontrib>Sartori, Luca</creatorcontrib><creatorcontrib>Varasi, Mario</creatorcontrib><creatorcontrib>Mercurio, Ciro</creatorcontrib><title>Discovery of Reversible Inhibitors of KDM1A Efficacious in Acute Myeloid Leukemia Models</title><title>ACS medicinal chemistry letters</title><addtitle>ACS Med. Chem. Lett</addtitle><description>Lysine-specific demethylase 1 (LSD1 or KDM1A) is a FAD-dependent enzyme that acts as a transcription corepressor or coactivator by regulating the methylation status of histone H3 lysines K4 and K9, respectively. KDM1A represents an attractive target for cancer therapy. While, in the past, the main medicinal chemistry strategy toward KDM1A inhibition was based on the optimization of ligands that irreversibly bind the FAD cofactor within the enzyme catalytic site, we and others have also identified reversible inhibitors. Herein we reported the discovery of 5-imidazolylthieno[3,2-b]pyrroles, a new series of KDM1A inhibitors endowed with picomolar inhibitory potency, active in cells and efficacious after oral administration in murine leukemia models.</description><subject>Letter</subject><issn>1948-5875</issn><issn>1948-5875</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqFkU9rGzEQxUVpaFI3XyHo2IsT_V_tpWAcpwmxCZQWchNa7WytdHflSrsGf_vK2A3xKacZmN-8kd5D6IqSa0oYvbEudVC7NXQtDMN1WRGiiPiALmgp9FTqQn5805-jzym9ZKQsCvIJnXMmuOSaXqDnW59c2ELc4dDgH5C75KsW8EO_9pUfQkz7wePtis7womm8s86HMWHf45kbB8CrHbTB13gJ4x_ovMWrUEObvqCzxrYJLo91gn7dLX7O76fLp-8P89lyaiXjw1Q4SepCM8JIyZ2sHVWWAtFCigqc1EIwxyiVWhVcVbrmWkleElcBE0qVjE_Qt4PuZqz2jkA_RNuaTfSdjTsTrDenk96vze-wNQXjikmZBb4eBWL4O0IaTJctgba1PeSPGiaI5HuUZlQdUBdDShGa1zOUmH0s5jQWc4wlL169feTr2v8cMsAOQBYwL2GMffbsPdV_ao-eag</recordid><startdate>20200514</startdate><enddate>20200514</enddate><creator>Romussi, Alessia</creator><creator>Cappa, Anna</creator><creator>Vianello, Paola</creator><creator>Brambillasca, Silvia</creator><creator>Cera, Maria Rosaria</creator><creator>Dal Zuffo, Roberto</creator><creator>Fagà, Giovanni</creator><creator>Fattori, Raimondo</creator><creator>Moretti, Loris</creator><creator>Trifirò, Paolo</creator><creator>Villa, Manuela</creator><creator>Vultaggio, Stefania</creator><creator>Cecatiello, Valentina</creator><creator>Pasqualato, Sebastiano</creator><creator>Dondio, Giulio</creator><creator>So, Chi Wai Eric</creator><creator>Minucci, Saverio</creator><creator>Sartori, Luca</creator><creator>Varasi, Mario</creator><creator>Mercurio, Ciro</creator><general>American Chemical Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4915-5903</orcidid><orcidid>https://orcid.org/0000-0003-0367-8290</orcidid></search><sort><creationdate>20200514</creationdate><title>Discovery of Reversible Inhibitors of KDM1A Efficacious in Acute Myeloid Leukemia Models</title><author>Romussi, Alessia ; Cappa, Anna ; Vianello, Paola ; Brambillasca, Silvia ; Cera, Maria Rosaria ; Dal Zuffo, Roberto ; Fagà, Giovanni ; Fattori, Raimondo ; Moretti, Loris ; Trifirò, Paolo ; Villa, Manuela ; Vultaggio, Stefania ; Cecatiello, Valentina ; Pasqualato, Sebastiano ; Dondio, Giulio ; So, Chi Wai Eric ; Minucci, Saverio ; Sartori, Luca ; Varasi, Mario ; Mercurio, Ciro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a523t-4c50d78202093c5dc16a1e08454bec58442c211586736b8d3865390cbe2466923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Letter</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Romussi, Alessia</creatorcontrib><creatorcontrib>Cappa, Anna</creatorcontrib><creatorcontrib>Vianello, Paola</creatorcontrib><creatorcontrib>Brambillasca, Silvia</creatorcontrib><creatorcontrib>Cera, Maria Rosaria</creatorcontrib><creatorcontrib>Dal Zuffo, Roberto</creatorcontrib><creatorcontrib>Fagà, Giovanni</creatorcontrib><creatorcontrib>Fattori, Raimondo</creatorcontrib><creatorcontrib>Moretti, Loris</creatorcontrib><creatorcontrib>Trifirò, Paolo</creatorcontrib><creatorcontrib>Villa, Manuela</creatorcontrib><creatorcontrib>Vultaggio, Stefania</creatorcontrib><creatorcontrib>Cecatiello, Valentina</creatorcontrib><creatorcontrib>Pasqualato, Sebastiano</creatorcontrib><creatorcontrib>Dondio, Giulio</creatorcontrib><creatorcontrib>So, Chi Wai Eric</creatorcontrib><creatorcontrib>Minucci, Saverio</creatorcontrib><creatorcontrib>Sartori, Luca</creatorcontrib><creatorcontrib>Varasi, Mario</creatorcontrib><creatorcontrib>Mercurio, Ciro</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>ACS medicinal chemistry letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Romussi, Alessia</au><au>Cappa, Anna</au><au>Vianello, Paola</au><au>Brambillasca, Silvia</au><au>Cera, Maria Rosaria</au><au>Dal Zuffo, Roberto</au><au>Fagà, Giovanni</au><au>Fattori, Raimondo</au><au>Moretti, Loris</au><au>Trifirò, Paolo</au><au>Villa, Manuela</au><au>Vultaggio, Stefania</au><au>Cecatiello, Valentina</au><au>Pasqualato, Sebastiano</au><au>Dondio, Giulio</au><au>So, Chi Wai Eric</au><au>Minucci, Saverio</au><au>Sartori, Luca</au><au>Varasi, Mario</au><au>Mercurio, Ciro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discovery of Reversible Inhibitors of KDM1A Efficacious in Acute Myeloid Leukemia Models</atitle><jtitle>ACS medicinal chemistry letters</jtitle><addtitle>ACS Med. Chem. Lett</addtitle><date>2020-05-14</date><risdate>2020</risdate><volume>11</volume><issue>5</issue><spage>754</spage><epage>759</epage><pages>754-759</pages><issn>1948-5875</issn><eissn>1948-5875</eissn><abstract>Lysine-specific demethylase 1 (LSD1 or KDM1A) is a FAD-dependent enzyme that acts as a transcription corepressor or coactivator by regulating the methylation status of histone H3 lysines K4 and K9, respectively. KDM1A represents an attractive target for cancer therapy. While, in the past, the main medicinal chemistry strategy toward KDM1A inhibition was based on the optimization of ligands that irreversibly bind the FAD cofactor within the enzyme catalytic site, we and others have also identified reversible inhibitors. Herein we reported the discovery of 5-imidazolylthieno[3,2-b]pyrroles, a new series of KDM1A inhibitors endowed with picomolar inhibitory potency, active in cells and efficacious after oral administration in murine leukemia models.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>32435381</pmid><doi>10.1021/acsmedchemlett.9b00604</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-4915-5903</orcidid><orcidid>https://orcid.org/0000-0003-0367-8290</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1948-5875 |
ispartof | ACS medicinal chemistry letters, 2020-05, Vol.11 (5), p.754-759 |
issn | 1948-5875 1948-5875 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7236255 |
source | EZB-FREE-00999 freely available EZB journals; PubMed Central; American Chemical Society Journals |
subjects | Letter |
title | Discovery of Reversible Inhibitors of KDM1A Efficacious in Acute Myeloid Leukemia Models |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A02%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discovery%20of%20Reversible%20Inhibitors%20of%20KDM1A%20Efficacious%20in%20Acute%20Myeloid%20Leukemia%20Models&rft.jtitle=ACS%20medicinal%20chemistry%20letters&rft.au=Romussi,%20Alessia&rft.date=2020-05-14&rft.volume=11&rft.issue=5&rft.spage=754&rft.epage=759&rft.pages=754-759&rft.issn=1948-5875&rft.eissn=1948-5875&rft_id=info:doi/10.1021/acsmedchemlett.9b00604&rft_dat=%3Cproquest_pubme%3E2405336251%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2405336251&rft_id=info:pmid/32435381&rfr_iscdi=true |